



By Carolyn Gretton

► PHARMACEUTICAL POOL

Alex AZAR
Maria CROWE
Dave RICKS

LILLY MAKES MANAGEMENT CHANGES



Lilly has announced a number of key management appointments. Alex Azar has been promoted to president of Lilly USA, the company's largest affiliate. Mr. Azar has been VP of U.S. managed healthcare services and Puerto Rico since 2009.



Lilly has promoted Maria Crowe to president of manufacturing operations, from senior VP for global drug product manufacturing. Ms. Crowe has responsibility for leading Lilly's network of 22 sites in 13 countries, as well as the company's global contract manufacturing organization.



Dave Ricks, formerly president of Lilly USA, has been promoted to senior VP and president of Lilly Bio-Medicines, which encompasses the therapeutic areas of neuroscience, cardiovascular, autoimmunity, musculoskeletal, and urology. Mr. Ricks' responsibilities include the United States, Japan, and Europe.

Dr. Hyam LEVITSKY
Dr. Harsukh PARMAR

ROCHE ADDS TWO RESEARCH HEADS



Global life-sciences company Roche has appointed Hyam Levitsky, M.D., head of cancer immunology experimental medicine within the pharma research and early development organization. Dr. Levitsky is responsible for guiding research and early development programs focused on the immunotherapy of cancer, overseeing experimental medicine studies and projects in collaboration with internal or external partners.



Dr. Levitsky joins Roche from the Johns Hopkins University School of Medicine, where he has been professor of oncology, medicine, and urology and an active staff member in oncology and medicine at the Johns Hopkins Hospital since 2002. As part of his work with Roche, he continues to hold an academic appointment at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center where he maintains his ongoing research program.

In other moves, Harsukh Parmar, M.D., has joined Roche as head of translational and experimental medicine for the inflammation discovery

and translational area. Dr. Parmar drives the strategy and implementation of early clinical development in inflammation and is accountable for TM's role in delivering innovative compounds to the life-cycle investment point.

Dr. Parmar was most recently with AstraZeneca in the United Kingdom as early development director, VP and global head of early clinical development in the respiratory and inflammation therapeutic area.

He received a medical degree from the University of Aberdeen, Scotland, and did postgraduate research at Westminster and Charing Cross Hospitals.

Dr. David MEEKER

SANOFI NAMES GENZYME CEO



Global healthcare company Sanofi has appointed David Meeker, M.D., as CEO of its Genzyme unit. Under Dr. Meeker's leadership, Genzyme is incorporating the rare disease business and the multiple sclerosis franchise.

Previous Genzyme divisions — renal, biosurgery, and oncology — have been integrated within the existing Sanofi portfolio, giving them greater global scale and capabilities.

Dr. Meeker received his M.D. from the University of Vermont Medical School, and completed the Advanced Management Program at Harvard Business School in 2000.

Dr. Frank MORICH

TAKEDA NAMES NYCOMED CEO



Japan-based Takeda Pharmaceutical Co. Ltd. has appointed Frank Morich, M.D., Ph.D., CEO of Nycomed as part of Takeda's completion of its Nycomed acquisition.

Dr. Morich is currently executive VP, international operations (Americas/Europe), for Takeda Pharmaceuticals International, a wholly owned subsidiary of Takeda America Holdings.

► BIOTECHNOLOGY POOL

Anthony (Tony) HOOPER

BMS VETERAN JOINS AMGEN EXECUTIVE TEAM



Global biotechnology company Amgen has named Anthony (Tony) Hooper, executive VP, global commercial operations.

Mr. Hooper joins Amgen after 16 years at Bristol-Myers Squibb (BMS), where he was

most recently senior VP, commercial operations and president, United States, Japan, and intercontinental.

Dr. Henry LOWMAN

CYTOMX PROMOTES SCIENTIFIC CHIEF



CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, has promoted Henry Lowman, Ph.D., to chief scientific officer. Dr. Lowman is leading research and development activities to advance the company's Probody candidates through optimization, preclinical, and early clinical development.

Dr. Lowman joined CytomX in September 2010 as VP of research. He received a Ph.D. in chemistry at Purdue University.

Dr. Hana MORAN

GALENA BIOPHARMA APPOINTS REGULATORY VP



Galena Biopharma, a biotechnology company focused on developing targeted oncology treatments that address major unmet medical needs to advance cancer care, has named Hana

Moran, Ph.D., VP, regulatory affairs and compliance.

Dr. Moran has more than 25 years of pharmaceutical industry experience in research, regulatory affairs, and quality assurance in startup and high-growth companies including SangStat, Scios, Athena Neurosciences, Intarcia, and Hana Biosciences.

She earned an M.Sc. in chemical engineering from Slovak Technical University in Bratislava, Slovakia and a Ph.D. in organic chemistry from the Weizmann Institute of Science in Rehovoth, Israel.

Dr. Edward WIRTH

SPINAL CORD INJURY RESEARCHER JOINS INVIVO THERAPEUTICS



InVivo Therapeutics Holdings has named spinal cord injury (SCI) researcher Edward Wirth, M.D., Ph.D., chief science officer (CSO).

Dr. Wirth is responsible for leading InVivo's first human clinical study for acute SCI using the company's proprietary scaffold without drugs or cells.

Before joining InVivo, Dr. Wirth led the embryonic stem cell clinical trial as medical director for regenerative medicine at Geron. He received a Ph.D. in neuroscience and an M.D. from the University of Florida.

► BIOPHARMACEUTICAL POOL

John BUTLER

Dr. Michael GRIFFITH

**INSPIRATION BIOPHARMACEUTICALS
NAMES EXECUTIVES**



Inspiration Biopharmaceuticals, a biopharmaceutical company focused on the development and commercialization of new treatment options for people with hemophilia, has appointed John Butler as CEO.

Mr. Butler brings to Inspiration more than 20 years of experience commercializing innovative therapies, most recently leading businesses that serve rare disease patient populations. He succeeds Michael Griffith, Ph.D., who has assumed the role of chief scientific officer and retains the position of president.

Dr. Michael CURTIS

**CATABASIS PHARMACEUTICALS
PROMOTES REGULATORY VP**



Catabasis Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids to create therapeutics for the treatment of inflammatory and metabolic diseases, has promoted Michael Curtis, Ph.D., to senior VP, product development and regulatory affairs.

In addition to leading the company's product development strategy, Dr. Curtis is responsible for chemistry, manufacturing and controls functions, toxicology, and regulatory approvals. He joined Catabasis in September 2010 as VP of product development.

Dr. Kathleen METTERS

LYCERA NAMES FORMER MERCK VP CEO



Lycera Corp., a biopharmaceutical company developing novel oral medicines to treat autoimmune diseases, has appointed Kathleen Metters, Ph.D., president and CEO. Dr. Metters joins Lycera after more than 20 years with Merck, where she most recently served as senior VP of external discovery and preclinical sciences. She received a Ph.D. in biochemistry from Imperial College of Science and Technology in London.

Dr. Stephen PEROUTKA

**NEUROGESX SELECTS CHIEF MEDICAL
OFFICER**

NeurogesX, a biopharmaceutical company focused

on developing and commercializing novel pain management therapies, has named Stephen Peroutka, M.D., Ph.D., executive VP and chief medical officer. Dr. Peroutka is responsible for NeurogesX's research and development, as well as regulatory and medical affairs.

Dr. Peroutka most recently served as VP, scientific affairs at PRA. He received an M.D. and a Ph.D. from the John Hopkins University School of Medicine.



Dr. Franck ROUSSEAU

TRANZYME APPOINTS MEDICAL CHIEF



Franck Rousseau, M.D., has joined Tranzyme Pharma as chief medical officer. Dr. Rousseau is responsible for overseeing the development of Tranzyme's clinical and preclinical portfolio. Tranzyme is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders.

Dr. Rousseau most recently served as therapeutic area head and VP hepatic diseases for Gilead Sciences. He received a doctorate of medicine from the University of Paris 7.

► SPECIALTY POOL

Dr. Paul AUDHYA

Dr. Hilary MALONE

Sean NOLAN

Jim ROUSE

**REATA PHARMACEUTICALS BOLSTERS
LEADERSHIP**



Reata Pharmaceuticals has announced a significant expansion of its management team to support the company's lead anti-inflammatory program, baradoxolone methyl, and to continue advancing its earlier-stage pipeline.

Paul Audhya, M.D., has joined Reata as VP of development and chief medical officer. Dr. Audhya has more than 15 years of experience, having led drug development in multiple therapeutic areas, including renal disease, at Johnson & Johnson, The Liposome Company, Bristol-Myers Squibb, Amgen, and Abbott Laboratories. He earned a doctorate from New York University School of Medicine and an MBA from the Graziadio School of Business and Management at Pepperdine University.

Hilary Malone, Ph.D., has been named VP and

chief regulatory and compliance officer. Dr. Malone joins Reata from Pfizer, where she was most recently senior VP and head of worldwide regulatory strategy. She received a doctorate in molecular neuropharmacology from the University of Dundee in Scotland.

Sean Nolan has been appointed VP and chief commercial officer. Mr. Nolan has 20 years of pharmaceutical industry experience. He was previously president of H. Lundbeck's U.S. entity.

Jim Rouse has joined Reata as VP and chief information officer. Most recently, Mr. Rouse was executive director of information technology at PharmaNet Development Group. He has a master's degree in information management from Stevens Institute of Technology.

Eric PAUWELS

**NPS PHARMACEUTICALS BOLSTERS
EXECUTIVE TEAM**



NPS Pharmaceuticals, a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, has appointed Eric Pauwels senior VP and chief commercial officer. Mr. Pauwels most recently was chief marketing officer for Accuray.

► DIAGNOSTIC POOL

Cyrille VILLENEUVE

Dr. Dana WASHBURN

LANTHEUS MEDICAL PROMOTES TWO



Lantheus Medical Imaging, a developer, manufacturer, and distributor of diagnostic imaging agents, has promoted Cyrille Villeneuve to chief commercial officer, from VP and general manager, international.



Mr. Villeneuve is responsible for directing the company's global commercial strategy, which includes providing leadership for U.S. sales and marketing in addition to the company's international business units. He earned a master's degree in public administration from École Nationale d'Administration Publique.

In other moves, Dana Washburn, M.D., has been promoted to chief medical officer, from VP, clinical development and medical affairs. Dr. Washburn is responsible for leading clinical development, medical affairs, and regulatory affairs for Lantheus.

He earned an M.D. from the University of Massachusetts Medical School and is a fellow of the American College of Cardiology.

► EMERGING POOL

Dr. Jakob DUPONT

FORMER GENENTECH EXECUTIVE JOINS ONCOMED AS RESEARCH VP



OncoMed Pharmaceuticals, a privately held company developing novel therapeutics that target cancer stem cells, has named Jakob Dupont, M.D., VP, clinical research.

Dr. Dupont was previously global medical director for Avastin at Genentech.

Dr. Dupont received his medical degree at Cornell University Medical College in New York and continued his training in internal medicine at the University of Michigan and New York-Presbyterian Hospital.

► AGENCY POOL

Luke DICKINSON

SPECTRUM HIRES ACCOUNT DIRECTOR



Luke Dickinson has rejoined independent health and science communications firm Spectrum as account director.

A former Spectrum intern, Mr. Dickinson brings with him several years of valuable experience in the areas of corporate branding, product launches, crisis management, and public affairs. He most recently worked on the corporate and public affairs team at Levick Strategic Communications.

Anders EKMAN

SAATCHI & SAATCHI SELECTS MANAGING DIRECTOR



Publicis Healthcare Communications Group announced that Anders Ekman has been named managing director of Saatchi & Saatchi Health Communications New York. Mr. Ekman joins Saatchi

& Saatchi from Performant, an organization he founded in 2010.

Jose FERREIRA

Paulette MCCARRON

Jim ROHN

COMPAS MAKES APPOINTMENTS

Healthcare media buyer Compas has announced

the promotion of Jose Ferreira, to manager, ByDoctor and data assets, from project manager, ByDoctor and data assets. Mr. Ferreira is responsible for managing the ByDoctor suite of products, which offers clients insight into HCP promotional access.



At Compas' sister company, Communications Media (CMI), Paulette McCarron has been promoted to VP, group account director, from VP, account director. Ms. McCarron's responsibilities include growing the media planning business with clients and mentoring CMI's account directors.

Also at Compas, Jim Rohn has been appointed account manager, buying services and deliverables. Mr. Rohn joins Compas from Advanced Health Media.

Mark FLEISCHER

KNOWLEDGEPOINT360 TAPS GROUP PRESIDENT FOR PHYSICIANS WORLD BUSINESSES



KnowledgePoint360 Group has named Mark Fleischer group president of both the Physicians World communications division and the Physicians World Speakers Bureau. Mr. Fleischer was previously senior VP and general manager North America for Cegedim Dendrite.

Kim NUSSLOCK

Ashley OXENDALE

ABELSONTAYLOR PROMOTES TWO



Independent healthcare advertising agency AbelsonTaylor has promoted Kim Nusslock to senior account executive, from account executive. Ms. Nusslock is responsible for a rheumatology product. During her tenure, she has also worked on products in the areas of cardiology and hypertension.



In other moves, Ashley Oxendale has been promoted to senior account executive, from account executive. Ms. Oxendale is responsible for several pediatric products, including an infant formula, prenatal vitamins, and infant bottles.

► CONSULTING POOL

Mertie SNEAD

CIS ADDS GLOBAL CLINICAL R&D HEAD

Mertie Snead has joined life-sciences consulting firm Compliance Implementation Services (CIS) as VP, clinical compliance, overseeing the company's



global clinical R&D practice group. Ms. Snead previously spent 19 years at a major pharmaceutical company, where she most recently held the position of director/head of global quality and compliance externalization.

► CRO POOL

Tilly BEAZELEY

PREMIER RESEARCH ADDS SENIOR DIRECTOR



Clinical development services provider Premier Research Group has appointed Tilly Beazeley senior director, business development, responsible for covering the United Kingdom and Scandinavia. Ms. Beazeley was most recently sales director at JBL.

Dr. Raymond KAISER

COVANCE STRENGTHENS BIOTECHNOLOGY SERVICES LEADERSHIP



Drug development services provider Covance has named Raymond Kaiser, Ph.D., global science leader and VP for biotechnology services. Dr. Kaiser was previously executive director of bioprocess research and development at Merck Research Laboratories.

John LARUS

CLINIPACE BROADENS CLINICAL DEVELOPMENT EXPERTISE



Clinipace Worldwide, a global digital clinical research organization (dCRO) focused on technology-amplified contract research services, has appointed John Larus executive VP of clinical operations. Mr. Larus' responsibilities include providing leadership and direction to the project management, clinical monitoring, and safety groups within the U.S. clinical operations unit.

Mr. Larus was previously chief operating officer at Fulcrum Pharma Developments. He received an M.A. in quantitative psychology from the University of North Carolina at Chapel Hill.

Dr. John POTTHOFF

THEOREM CLINICAL RESEARCH ANNOUNCES CEO

Global full-service CRO Theorem Clinical Research, previously Omnicare Clinical Research, has ap-



pointed John Potthoff, Ph.D., president and CEO. Dr. Potthoff succeeds James Pusey, M.D., who has been elevated to executive chairman. Dr. Potthoff most recently held the role of chief operating officer at INC Research.

Steven **SKOLSKY**

QUINTILES APPOINTS CDO HEAD



Quintiles has named Steven Skolsky global head of its clinical and data operations (CDO) unit, which unites clinical data management and clinical operations under one umbrella to accelerate data flow and ensure the quality of Quintiles' data. A 30-year veteran of the biopharmaceutical industry, Mr. Skolsky was most recently vice chairman for Basilea Pharmaceutica.

Catherine (Cathy) **TYNER**

NOVELLA CLINICAL LAUNCHES ENHANCED CLINICAL OVERSIGHT GROUP



Catherine (Cathy) Tyner has joined full-service contract research organization Novella Clinical as executive director, oversight group management, as part of its expansion of services related to the integrated design and implementation of clinical oversight groups.

Ms. Tyner was previously a senior director in Quintiles' lifecycle safety unit. She received two master's degrees from Bowling Green State University.

► **SERVICE POOL**

Justin **HAWVER**

Debbie **MALOVETZ**

Stephen **PRYBELLA**

MTI STRENGTHENS ANALYTICS TEAM



MTI, a developer of professional relationship management (PRM) programs, has added business analytics specialists and a VP in a move to broaden its development of segmentation, resource allocation, test and learn, and measurement activity services.



Justin Hawver has joined MTI as a business analytics specialist.



Debbie Malovetz has been named VP, strategic services, responsible for the overall management of client relationships and serving as a PRM strategic consultant to pharmaceutical brand teams while developing new business opportunities within key accounts. Ms. Malovetz was previously

VP, client development with M3 Health.

Stephen Prybella has been appointed a business analytics specialist. Mr. Prybella was most recently a manager within the analytics department at First Equity Card Corporation.

Gerald **MELILLO JR.**

PDI NAMES BUSINESS DEVELOPMENT VP



Gerald Melillo Jr. has joined PDI as senior VP of business development, responsible for providing leadership and strategy to help drive the company's commercial outsource services and contract sales business. Mr. Melillo was previously general manager of the southeast operating unit for Novartis Pharmaceuticals.

Colin **STANLEY**

ICON PROMOTES DOCS PRESIDENT



Icon, a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries, has promoted Colin Stanley to president of DOCS, the company's global resourcing division.

Mr. Stanley joined Icon in 2001 and was most recently chief operating officer of DOCS.

► **TECHNOLOGY POOL**

David **AVAKIAN**

PHT ADDS CHIEF ARCHITECT

PHT has appointed David Avakian as chief architect, responsible for leading the design process for soft-



ware, systems, and infrastructure of the PHT ePRO system.

Mr. Avakian previously worked at Phase Forward.

Bryan **SPIELMAN**

MEDIDATA SOLUTIONS APPOINTS CORPORATE DEVELOPMENT VP



Medidata Solutions, a provider of SaaS-based clinical development solutions, has named Bryan Spielman executive VP of strategy and corporate development. Mr. Spielman was previously partner and managing director at Centerview Partners. He received an MBA from New York University's Stern School of Business.

Dr. Wolfgang **SUMMA**

INVIVODATA APPOINTS WORLDWIDE OPERATIONS VP



invivodata, a provider of electronic patient reported outcomes (ePRO) solutions and services for global clinical research, has named Wolfgang Summa, Ph.D., VP of worldwide operations. Dr. Summa is responsible for managing the successful implementation of invivodata's ePRO solutions in clinical trials around the world. He rejoins the company after having previously served as VP of Europe and Asia. **PV**



USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0112-Pool



Pharma**VOICE** MarketPlace.com



**More than 5,500
Solutions Providers**

The most comprehensive online directory of products and services for the life-sciences industry — featuring a wide range of products, services, and solutions for your clinical, commercial, business, and technology needs.

Browse by Category • Search by Company

www.pharmavoicemarketplace.com

► PHARMACEUTICAL POOL

Cuong Viet **DO**

MERCK APPOINTS STRATEGY CHIEF

Merck has appointed Cuong Viet Do chief strategy officer, responsible for both developing and executing enterprise-wide strategy and further building connections between the current and future business plans of the global pharmaceutical company's franchises, divisions, and functions.

Mr. Do joins Merck after serving as senior VP of corporate strategy and business development at TE Connectivity, formerly Tyco Electronics. He received an MBA from the Tuck School of Business at Dartmouth College.

► BIOTECHNOLOGY POOL

J. Scott **GARLAND**

EXELIXIS CREATES COMMERCIAL CHIEF ROLE

Exelixis has appointed J. Scott Garland executive VP and chief commercial officer, reflecting the biotechnology company's continued transformation into a commercial organization. Mr. Garland is overseeing the commercial functions of marketing, sales, and commercial operations, and collaborating closely with Exelixis' development and manufacturing teams to provide commercial perspective for cabozantinib development efforts across multiple oncology indications.

Mr. Garland joins Exelixis from Genentech, where he previously served as VP of the Avastin franchise. He received an MBA from Duke University's Fuqua School of Business.

► BIOPHARMACEUTICAL POOL

Craig **FRASER**

FORMER PFIZER VP JOINS AEGERION PHARMACEUTICALS

Aegerion Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, has named Craig Fraser president, U.S. Mr. Fraser joins Aegerion from Pfizer, where he was most recently VP, global disease areas.

Dr. Kenneth **HILLAN**

ACHAOGEN PROMOTES MEDICAL CHIEF TO CEO

Achaogen, a biopharmaceutical company discovering and developing treatments for life-threatening, multi-drug resistant (MDR) Gram-negative bac-

terial infections, has appointed Chief Medical Officer Kenneth Hillan, M.B., Ch.B., to the additional role of CEO. He holds an M.B., Ch.B. (Bachelor of Medicine and Surgery) from the University of Glasgow.

Dr. Jennifer **JACKSON**

CUBIST PHARMACEUTICALS NAMES REGULATORY AFFAIRS VP

Jennifer Jackson, Ph.D., has joined Cubist Pharmaceuticals as senior VP of regulatory affairs. Cubist is a biopharmaceutical company focused on the research, development, and commercialization of products that address significant unmet medical needs in the acute care environment.

Dr. Jackson was most recently VP of regulatory affairs and clinical compliance for Biogen Idec Hemophilia.

Bob **REPELLA**

VANDA PHARMACEUTICALS APPOINTS COMMERCIAL CHIEF

Vanda Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, has named Bob Repella senior VP, chief commercial officer. Mr. Repella has more than 25 years of experience in the biotech/pharmaceutical industry, most recently as Cephalon's senior VP of pharmaceutical operations for the Americas region.

Dr. John **SCARLETT**

GERON APPOINTS CHIEF EXECUTIVE

John Scarlett, M.D., has become CEO of Geron, a developer of biopharmaceuticals for the treatment of cancer, as well as cell therapies from differentiated human embryonic stem cells for a range of conditions, including spinal cord injury.

Dr. Scarlett brings to Geron more than 25 years of executive leadership experience in the pharmaceutical and biotechnology industry, most recently as president and CEO of Proteolix.

Dr. Raymond **URBANSKI**

FORMER PFIZER EXECUTIVE JOINS METABOLEX

Metabolex, a biopharmaceutical company focused on the discovery and development of new medicines to treat metabolic diseases, has appointed Raymond Urbanski, M.D., Ph.D., chief medical officer. Dr. Urbanski joins Metabolex from Pfizer, where he was VP and medical head of the established products business unit. He received a Ph.D. in pharmacology and an M.D. from the University of Medicine and Dentistry of New Jersey.

► SPECIALTY POOL

Dr. H. Daniel **PEREZ**

PRESIDIO PHARMACEUTICALS MAKES LEADERSHIP TRANSITION

Presidio Pharmaceuticals has appointed H. Daniel Perez, M.D., president and CEO. Dr. Perez succeeds Co-Founder Dr. Omar Haffar.

Dr. Perez's responsibilities include working closely with the Presidio management team and investors to continue research and development efforts on the company's novel small molecule programs directed to patients infected with the hepatitis C virus.

► GENOMICS POOL

Dr. Sammy **FARAH**

SGVI NAMES PRESIDENT

Synthetic Genomics Vaccines (SGVI), a privately held company focused on developing next-generation vaccines using genomic sequencing and synthetic genomic technologies, has named Sammy Farah, Ph.D., president.

Dr. Farah has extensive vaccine expertise and more than 15 years of scientific, business, and executive management experience in the biotechnology industry.

He was most recently chief business officer for Immune Design.

Dr. Farah received an MBA from the Wharton School of the University of Pennsylvania and a Ph.D. in biochemical engineering from Stanford University.

► AGENCY POOL

Laura **FINLEY**

Dana **GULICK**

Dena **KOKLANARIS**

Lindsay **PAUL**

Brandon **SKOP**

Amy **STRATHERN**

COONEY/WATERS GROUP ADDS STAFF

Cooney/Waters Group, a group of healthcare communications companies, has announced several staff additions and promotions at its brands, Cooney/Waters and Alembic Health Communications.

Laura Finley has been promoted to account supervisor at Cooney/Waters.

Dana Gulick has joined Cooney/Waters as managing supervisor, with responsibility for

Talent Pool

the firm's work with UCB in the United States. Ms. Gulick was most recently with Racepoint Group, where she spearheaded global programming for clients spanning the medical device, biotechnology, and healthcare IT industries.

Dena Koklanaris has been named managing supervisor responsible for managing Cooney/Waters' work in the United States with UCB. Ms. Koklanaris was previously with Edelman's health and wellness practice, where she led public relations and communications programming for top-tier global pharmaceutical clients with a focus on women's health.

At Alembic Health Communications, Lindsay Paul has been promoted to managing supervisor.

Brandon Skop and Amy Strathern have each been promoted to account supervisor for Cooney/Waters.

► CRO POOL

Dr. Andrzej (Andy) DZIK-JURASZ

BIOCLINICA EXPANDS MEDICAL AFFAIRS GROUP

BioClinica, a global provider of clinical trial management solutions, has named Andrzej (Andy)

Dzik-Jurasz, M.D., Ph.D., as senior medical director for medical affairs, helping to support growth initiatives within the company's imaging core lab solutions business.

Dr. Dzik-Jurasz most recently served as Novartis' executive director, global head oncology translational imaging.

Dr. Dzik-Jurasz received his medical degree from Westminster Medical School, London, UK, and his Ph.D. from the Institute of Cancer Research, London, UK. He is a Fellow of the Royal College of Surgeons of England and Fellow of the Royal College of Radiologists.

► SERVICE POOL

Salvatore GUCCIONE

ACETO NAMES PRESIDENT

Aceto, a provider of sourcing, quality assurance, regulatory support, marketing and distribution services, has appointed Salvatore Guccione president and chief operating officer.

Mr. Guccione most recently served as an operating partner at Arsenal Capital Partners.

He received an MBA in finance from New York University's Stern School of Business.

Dr. Jan-Olav HENCK

APTUIT APPOINTS SCIENTIFIC CHIEF

Global pharmaceutical services company Aptuit has named Jan-Olav Henck, Ph.D., chief scientific officer.

Dr. Henck was most recently site director for what is now Aptuit's SSCI division. He holds a doctorate in physical chemistry.

Anand NARASIMHAN

IMPACTRX NAMES OPERATIONS VP

ImpactRx, a service provider measuring the impact of promotion on physician prescribing behavior, has named Anand Narasimhan executive VP, operations and technology.

Mr. Narasimhan is leading the design and execution of the company's operational and technology initiatives in support of its next phase of growth, including the expansion of its consulting analytics business.

Mr. Narasimhan joins ImpactRx from Symphony Services Corp., where he was most recently senior VP for enterprise business.

He has a postgraduate diploma in computer applications from the National Center for Computing Techniques in Bangalore, India. **PV**

Searching for the right audience for your next e-mail campaign?

Target Pharma**VOICE** Readers with your E-mail Marketing Campaign

- Segment our opt-in e-mail database of 65,000+
- 20% off multiple emails
- 50% off all resends
- Best practices for better ROI
- Design and html coding available

Call 215-321-8656 or e-mail
mwalsh@pharmavoice.com to
discuss your next email promotion with Marah Walsh.

Pharma**VOICE**






PATS ON THE BACK, HANDSHAKES, HIGH-FIVES. STANDARD WHEN YOU CHOOSE THE REINVENTED 2012 TOYOTA CAMRY AS YOUR FLEET VEHICLE.

With a history of low cost of ownership¹ and high retained value,¹ the Toyota Camry is the best long-term value for your fleet vehicle.² There are many reasons why Camry has been the best-selling car in America for 13 of the last 14 years.³ And now, the new Camry comes with safety innovations like never before. Including ten standard airbags and available blind spot monitoring.^{4,5} If you want to get praised for choosing the right fleet vehicle, look no further than the reinvented 2012 Toyota Camry. Call 1-800-732-2798 or visit fleet.toyota.com



Options shown. ¹2011 IntelliChoice, www.IntelliChoice.com; based on hybrid and 4-cyl. models. ²Based on Vincentric's 2011 Best Fleet Value in America analysis, mid-size sedan segment. ³MotorIntelligence.com, CY 1997-2010 sales. ⁴Do not rely exclusively on the Blind Spot Monitor to determine if a lane change is safe. Always look over your shoulder and use your turn signal before changing lanes. There are several limitations to the function, detection, range and clarity of the monitor. For a complete list of limitations and directions regarding use of the monitor, please see the Owner's Manual. ⁵Available on XLE and Hybrid XLE models only. ©2011 Toyota Motor Sales, U.S.A., Inc.



WHEN IT COMES TO TRAINING IT'S WHAT'S INSIDE THAT COUNTS

Pharmaceutical Institute formulates training programs with a unique active ingredient: *actual experts*.

In fact, with access to some of the best minds in pharmaceuticals and biotech, we offer unmatched content expertise. That knowledge, plus our advanced course development skills, creates an unbeatable combination.

E-course series categories:

- Managed markets
- Sales
- Marketing
- Therapeutic areas
- Pharma and biotech industry

Each series includes a comprehensive collection of courses. Don't see exactly what you need? Custom course development is also available.

**CONTACT US TODAY FOR
EFFECTIVE, FAST-ACTING RELIEF.**

877.923.5600
919.844.5650
PHARMAINSTITUTE.COM



PHARMACEUTICAL
INSTITUTE

KNOWLEDGE FOR ACTION™

A Subsidiary of Campbell Alliance